Table 3 |
||||||
|
Incidence of leukopenia and neutropenia per schedule according to different age intervals |
||||||
| Combination (TAC) schedule (n = 450) |
Sequence schedule (n = 360) |
Combination dose-dense (ATdd) schedule (n = 121) |
Sequence dose-dense schedule (n = 86) |
|||
|
|
|
|||||
| Nontaxane |
Taxane |
Nontaxane (dose-dense epirubicin) |
Taxane (dose-dense paclitaxel) |
|||
|
|
||||||
| Leukopenia |
||||||
| Patients aged < 60 years |
878 (57.3) |
423 (43.4) |
419 (47.3) |
164 (50.2) |
82 (29.2) |
7 (2.6) |
| Patients aged 60 to 64 years |
175 (65.3) |
124 (53.9) |
107 (51.0) |
49 (61.3) |
20 (36.4) |
0 (0.0) |
| Patients aged > 64 years |
111 (64.9) |
99 (60.7) |
71 (49.0) |
25 (62.5) |
17 (42.5) |
1 (2.9) |
| Neutropenia |
||||||
| Patients aged < 60 years |
371 (37.5) |
455 (52.8) |
346 (45.3) |
136 (43.5) |
74 (29.7) |
20 (8.7) |
| Patients aged 60 to 64 years |
139 (56.7) |
106 (52.0) |
79 (44.1) |
37 (47.4) |
18 (36.7) |
2 (5.0) |
| Patients aged > 64 years |
91 (55.2) |
97 (65.5) |
61 (48.4) |
17 (43.6) |
11 (33.3) |
1 (3.2) |
| Febrile neutropenia |
||||||
| Patients aged < 60 years |
140 (9.3) |
9 (1.0) |
19 (2.5) |
14 (4.5) |
0 (0.0) |
0 (0.0) |
| Patients aged 60 to 64 years |
30 (11.3) |
1 (0.5) |
5 (2.8) |
4 (5.1) |
3 (6.4) |
0 (0.0) |
| Patients aged > 64 years |
24 (14.3) |
2 (1.4) |
1 (0.8) |
2 (5.1) |
0 (0.0) |
0 (0.0) |
|
|
||||||
|
Data presented as n (%). All percentage values are valid. TAC, docetaxel/doxorubicin/cyclophosphamide; ATdd, doxorubicin/docetaxel dose-dense. |
||||||
|
Loibl et al. Breast Cancer Research 2008 10:R77 doi:10.1186/bcr2144 |
||||||
